StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

Carbidopa

HCID 34359
Neue Reaktion
Drucken

Daten werden ergänzt – lade die Seite später neu, um den aktuellen Stand zu sehen

GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
28860-95-9
Standard-SMILES
C[C@@](Cc1ccc(O)c(O)c1)(NN)C(=O)O
InChIKey
TZFNLOMSOLWIDK-JTQLQIEISA-N
Summenformel
C10H14N2O4
Durchschnittliche Molmasse
226,23 g/mol
Monoisotopische Masse
226,09535693

Überblick

Carbidopa (anhydrous) is 3-(3,4-Dihydroxyphenyl)propanoic acid in which the hydrogens alpha- to the carboxyl group are substituted by hydrazinyl and methyl groups (S-configuration). Carbidopa is a dopa decarboxylase inhibitor, so prevents conversion of levodopa to dopamine. It has no antiparkinson activity by itself, but is used (commonly as its hydrate) in the management of Parkinson's disease to reduce peripheral adverse effects of levodopa. It has a role as an antiparkinson drug, a dopaminergic agent and an EC 4.1.1.28 (aromatic-L-amino-acid decarboxylase) inhibitor. It is a member of hydrazines, a monocarboxylic acid and a member of catechols.

Namen und Bezeichner

Bevorzugter Name
Carbidopa
IUPAC
(2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid
Englischer Name
S-(-)-Carbidopa
Summenformel
C10H14N2O4
Molmasse
226.23

Namen und Synonyme

carbidopa28860-95-9LodosynCarbidopa anhydrousN-Aminomethyldopa(S)-(-)-carbidopaalpha-MethyldopahydrazineCarbidopumL-alpha-Methyldopahydrazine(2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acidCarbidopa (anhydrous)(S)-carbidopa
Weitere Namen anzeigen
S(-)-CARBIDOPACarbidopa-d3mk486KINSONL-3-(3,4CARBIDOPA EDMFCarbidopa MonomerCARBIDOPAANHYDROUS
MK 486L-3-(3,4-Dihydroxyphenyl)-2-methyl-2-hydrazinopropionic acidMK-486DTXSID4022735(-)-L-alpha-Hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamic acidKR87B45RGH(alphaS)-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoic acidDTXCID502735

Datenbank-Bezeichner

CAS
28860-95-9、38821-49-7
PubChem CID
34359
DTXSID
DTXSID4022735
ChEMBL
CHEMBL1200748、CHEMBL1201236

Eigenschaften

Berechnete StruktureigenschaftenWird ergänzt

XLogP
-2,2
Polarare Oberfläche (TPSA)
116 Ų
H-Brücken-Donoren
5
H-Brücken-Akzeptoren
6
Frei drehbare Bindungen
4
Schwere Atome
16
Formalladung
0
Komplexität
261

Experimentelle und physikochemische Eigenschaften

Drugs · 2 Einträge

Pharmaceuticals -> Listed in ZINC15

Pharmaceuticals -> Used in Switzerland

LogP-1.9
Human Drugs · 3 Einträge

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Pharmaceuticals

Boiling PointDecomposes
Melting Point · 2 Einträge

203-208 °C

203 - 205 °C

Physical DescriptionSolid
Dissociation Constants2.3
Collision Cross Section · 2 Einträge

142.4 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

143.39 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

GHS-Klassifizierung

GHS Classification · 6 Einträge

This chemical does not meet GHS hazard criteria for 2.7% (2 of 75) of reports.

Danger

H315 (82.7%): Causes skin irritation [Warning Skin corrosion/irritation]

P203, P261, P264, P264+P265, P271, P280, P302+P352, P304+P340, P305+P351+P338, P318, P319, P321, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 75 reports by companies from 10 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Warning

Gefahrenhinweise

Regulatory InformationREACH registered substance: Carbidopa (EC: 249-271-9)
Hazard Classes and Categories · 2 Einträge

Skin Irrit. 2 (82.7%)

Muta. 2 (100%)

Toxikologische Informationen

Adverse Effects · 1 Eintrag

Because of the irreversible binding of AADC, carbidopa can decrease or deplete peripheral levels of serotonin, dopamine, norepinephrine, and epinephrine. Additionally, research has demonstrated that the irreversible binding of PLP causes nutritional deficiencies in vitamins B3 and B6. Specific carbidopa-induced dyskinesias, including “facial twitching and head bobbing,” have also been described.

Toxicity Summary · 1 Eintrag

There is little data to suggest a possibility for or symptoms of carbidopa toxicity. However, reported data indicate that carbidopa/levodopa intestinal gel infusion can cause significant damage to small nerve fibers leading to pain and sensory discomfort.

Chemie und Industrie

Pharmakologische Informationen

Protein BindingIt is widely accepted that the protein binding of carbidopa is 76%. However, more studies are required or the presentation of the source of this information.
Pharmacodynamics · 1 Eintrag

When mixed with [levodopa], carbidopa inhibits the peripheral conversion of [levodopa] to dopamine and the decarboxylation of [oxitriptan] to serotonin by aromatic L-amino acid decarboxylase. This results in an increased amount of [levodopa] and [oxitriptan] available for transport to the central nervous system. Carbidopa also inhibits the metabolism of [levodopa] in the GI tract, thus, increasing the bioavailability of [levodopa]. The presence of additional units of circulating [levodopa] can increase the effectiveness of the still functional dopaminergic neurons and it has been shown to alleviate symptoms for a time. The action of carbidopa is very important as [levodopa] is able to cross the blood-brain barrier while dopamine cannot. Hence the administration of carbidopa is essential to prevent the transformation of external [levodopa] to dopamine before reaching the main action site in the brain. The coadministration of carbidopa with [levodopa] has been shown to increase the half-life of [levodopa] more than 1.5 times while increasing the plasma level and decreasing clearance. The combination therapy has also shown an increase of the recovery of [levodopa] in urine instead of dopamine which proves a reduced metabolism. This effect has been highly observed by a significant reduction in [levodopa] requirements and a significant reduction in the presence of side effects such as nausea. It has been observed that the effect of carbidopa is not dose-dependent.

Mechanism of Action · 1 Eintrag

Carbidopa is an inhibitor of the DDC which in order, inhibits the peripheral metabolism of levodopa. DDC is very important in the biosynthesis of L-tryptophan to serotonin and the modification of L-DOPA to dopamine. DDC can be found in the body periphery and in the blood-brain barrier. The action of carbidopa is focused on peripheral DDC as this drug cannot cross the blood-brain barrier. Hence, it will prevent the metabolism of [levodopa] in the periphery but it will not have any activity on the generation of dopamine in the brain.

Biological Half-Life

Zugehörige Reaktionen

6
Reaktionsaufzeichnung erstellen
Reaktionsgleichung von HRID 452338
HRID 452338als Produkt
Reaktionsgleichung von HRID 452339
HRID 452339als Edukt
Reaktionsgleichung von HRID 2212438
HRID 2212438als Edukt
Reaktionsgleichung von HRID 2212446
HRID 2212446als Edukt
Reaktionsgleichung von HRID 2212452
HRID 2212452als Edukt
Reaktionsgleichung von HRID 2242762
HRID 2242762als Edukt

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
ChEBI
CHEBI:39585
UNII
KR87B45RGH
EC Number
249-271-9、657-445-4
Nikkaji
J17.160C

Physikochemische Eigenschaften

Schmelzpunkt
203 · 203-205° (dec); mp 208°
Siedepunkt
367.84 °C · 367.84°C (rough estimate)
Dichte
1.2616 · 1.2616 (rough estimate)
Brechungsindex
1.5 · 1.5000 (estimate)
storage temp.
-20 °C · -20°C
Löslichkeit
DMSO (Slightly), Methanol (Slightly)
pka
3.4 · 3.40±0.14(Predicted)
Aggregatzustand
powder
Farbe
White to Off-White
Stabilität
Unstable in Solution
InChI
InChI=1/C10H14N2O4/c1-10(12-11,9(15)16)5-6-2-3-7(13)8(14)4-6/h2-4,12-14H,5,11H2,1H3,(H,15,16)/t10-/s3
InChIKey
TZFNLOMSOLWIDK-JQHDBZEONA-N
SMILES
[C@@](C)(NN)(C(=O)O)CC1C=CC(O)=C(O)C=1 |&1:0,r|
CAS Datenbank
28860 · 28860-95-9(CAS DataBase Reference)
Drug Induced Liver Injury · 6 Einträge

Drug Induced Liver Injury Rank (DILIrank 2.0)

Carbidopa

Ambiguous-DILI-concern

3

Warnings & precautions

DOI:10.1016/j.drudis.2016.02.015

EPA Human Health Benchmarks for Pharmaceuticals · 6 Einträge

Carbidopa

1.6

6.9

Most patients respond to a 1:10 proportion of carbidopa and levodopa, provided the daily dosage of carbidopa is 70 mg or more a day.

Data used to generate the benchmarks include the following: Lowest Daily Dose (LDD): 70 mg/day, Lowest Therapeutic Dose (LTD): 0.9 mg/kg-day, and Screening Dose: 0.0003 mg/kg-day.

2-Jul-20

Sicherheitsdaten

wgk
3
RTECS-Nr.
MW5298000
Speicherklasse
11 - Combustible Solids
The reported half-life of carbidopa is of approximately 107 minutes.
Metabolism/Metabolites · 1 Eintrag

The loss of the hydrazine functional group (probably as molecular nitrogen) represents the major metabolic pathway for carbidopa. There are several metabolites of carbidopa metabolism including 3-(3,4-dihydroxyphenyl)-2-methylpropionic acid, 3-(4-hydroxy-3-methoxyphenyl)-2-methylpropionic acid, 3-(3-hydroxyphenyl)-2-methylpropionic acid, 3-(4-hydroxy-3-methoxyphenyl)-2-methyllactic acid, 3-(3-hydroxyphenyl)-2-methyllactic acid, and 3,4-dihydroxyphenylacetone (1,2).

FDA Pharmacological Classification · 5 Einträge

MNX7R8C5VO

CARBIDOPA

Established Pharmacologic Class [EPC] - Aromatic Amino Acid Decarboxylation Inhibitor

Mechanisms of Action [MoA] - DOPA Decarboxylase Inhibitors

Carbidopa is an Aromatic Amino Acid Decarboxylation Inhibitor. The mechanism of action of carbidopa is as a DOPA Decarboxylase Inhibitor.

MeSH Pharmacological Classification · 3 Einträge

Agents used in the treatment of Parkinson's disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists.

Any drugs that are used for their effects on dopamine receptors, on the life cycle of dopamine, or on the survival of dopaminergic neurons.

Compounds and drugs that block or inhibit the enzymatic action of AROMATIC AMINO ACID DECARBOXYLASES. Pharmaceutical agents in this category are used in conjunction with LEVODOPA in order to slow its metabolism.

Absorption, Distribution and Excretion · 4 Einträge

When [levodopa]/carbidopa is administered orally, 40-70% of the administered dose is absorbed. Once absorbed, carbidopa shows bioavailability of 58%. A maximum concentration of 0.085 mcg/ml was achieved after 143 min with an AUC of 19.28 mcg.min/ml.

In animal studies, 66% of the administered dose of carbidopa was eliminated via the urine while 11% was found in feces. These studies were performed in humans and it was observed a urine excretion covering 50% of the administered dose.

The volume of distribution reported for the combination therapy of carbidopa/[levodopa] is of 3.6 L/kg. However, carbidopa is widely distributed in the tissues, except in the brain. After one hour, carbidopa is found mainly in the kidney, lungs, small intestine and liver.

The reported clearance rate for the combination therapy of [levodopa]/carbidopa is 51.7 L/h.

Verwendung und Herstellung

UsesUse (kg; approx.) in Germany (2009): >5000
Use ClassificationPharmaceuticals

Anwendungen

Verwendenin combinaison with levodopa as antiparkinsonian;inhibits aromatic-L-amino-acid decarboxylase (DOPA Decarboxylase or DDC)

Vor- und nachgelagerte Produkte

Vorgelagerte Rohstoffe

p-VinylphenolSodium bisulfite water solutionDiethylamin, in wässriger LösungNatriumhydrogensulfit4-Hydroxyphenylacetonen-ButylaminNatriumcyanidVanillinNitroethanKaliumcyanidHydrogenchloridEisenHydrazine hydrateHydrogenbromidEssigsure
Ergänzende Hinweise · 1 Eintrag

DefinitionChEBI: 3-(3,4-Dihydroxyphenyl)propanoic acid in which the hydrogens alpha- to the carboxyl group are substituted by hydrazinyl and methyl groups (S-configuration). Carbidopa is a dopa decarboxylase inhibitor, so prevents conversi n of levodopa to dopamine. It has no antiparkinson activity by itself, but is used (commonly as its hydrate) in the management of Parkinson's disease to reduce peripheral adverse effects of levodopa.